Ignite Creation Date:
2024-05-06 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 1:53 PM
Study NCT ID:
NCT04705831
Status:
UNKNOWN
Last Update Posted:
2021-01-12
First Post:
2021-01-07
Brief Title:
Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection
Sponsor:
IMMUNOe Research Centers
Organization:
IMMUNOe Research Centers
Study Overview
Official Title:
A Randomized Double Blind Placebo Controlled Cross-Over Proof-of-Concept Study to Evaluate the Benefit of RUCONEST C1 Esterase Inhibitor Recombinant in Improving Neurological Symptoms in Post-SARS-CoV-2 Infection
Status:
UNKNOWN
Status Verified Date:
2021-01
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Randomized Double Blind Placebo Controlled Proof-of-Concept Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post-SARS-CoV-2 Infection
Detailed Description:
This study will last approximately 19 weeks including 16 infusions total each one week apart This is to help patients that have developed Post-Viral Fatigue Syndrome which can include symptoms such as extreme fatigue lost of taste brain fog andor seizures
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None